)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Ionis Pharmaceuticals
Ionis Pharmaceuticals (IONS) investor relations material
Ionis Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic evolution, positioning, and commercial progress
Transitioned from R&D to a fully integrated commercial-stage biotech, launching first two independent products, Tringulza and Donzera, in 2025.
Four approved medicines and six positive Phase III readouts, with 11 more in late-stage development.
Focused on delivering first- or best-in-class medicines in cardiometabolic and neurological diseases, with a deep late-stage pipeline and proven technology platform.
Strong financial foundation and disciplined expense management support ongoing investments and future launches.
Clear path to accelerating revenue growth, sustained positive cash flow, and substantial value creation, targeting cash flow break-even by 2028.
Product launches and pipeline highlights
Tringulza (Olezarsen) launched for FCS, showing strong efficacy, safety, and patient adherence, with $105 million in 2025 U.S. sales and EU launch underway.
Donzera approved for HAE prophylaxis, addressing unmet needs in efficacy, tolerability, and convenience, with a successful U.S. launch and European approval expected soon.
Olezarsen demonstrated up to 72% triglyceride reduction and 85% reduction in acute pancreatitis events in SHTG, with a supplemental NDA filed and launch expected in 2026.
Upgraded Olezarsen peak revenue guidance to over $2 billion based on strong market enthusiasm and clinical data.
Wainua and Qalsody continue to perform well, with Wainua showing strong uptake in hATTR polyneuropathy and anticipation for cardiomyopathy data.
Neurology and partner programs
Six wholly owned neurological medicines in clinical development, including Zolexarsen/Zilganersen for Alexander disease and ION582 for Angelman syndrome, both with breakthrough therapy designations.
Zolexarsen/Zilganersen showed unprecedented disease-modifying impact in Alexander disease, with NDA submission and launch planned for 2026.
ION582 for Angelman syndrome demonstrated consistent clinical improvements, with pivotal Phase III data expected in 2027.
Partner programs advancing, including Eplontersen for ATTR cardiomyopathy and Pelacarsen for Lp(a) cardiovascular disease, both with major Phase III data readouts in 2025.
Bepirovirsen for chronic HBV expected to be approved and launched by 2027, with additional partner launches planned.
Olezarsen's NNT for high-risk SHTG patients?
What drives DAWNZERA's encouraging launch?
What makes Zilganersen's results unprecedented?
What drives the $2B+ peak revenue for SHTG olezarsen?
Eplontersen combo data: Market impact vs. stabilizers?
Pelacarsen Lp(a): Minimum efficacy for launch?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ionis Pharmaceuticals earnings date
Q4 202518 Feb, 2026
Ionis Pharmaceuticals
Next Ionis Pharmaceuticals earnings date
Q4 202518 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ionis Pharmaceuticals Inc. discovers and develops RNA-targeted therapeutics. It applies antisense technology platforms to develop treatments for a range of genetic and rare diseases. The company is headquartered in Carlsbad, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage